Advertisement
Singapore markets close in 6 hours 48 minutes

  • Straits Times Index

    3,184.56
    +29.87 (+0.95%)
     

  • Nikkei

    37,916.00
    -45.80 (-0.12%)
     

  • Hang Seng

    16,288.92
    +37.08 (+0.23%)
     

  • FTSE 100

    7,847.99
    +27.63 (+0.35%)
     

  • Bitcoin USD

    61,841.21
    -2,428.90 (-3.78%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • Dow

    37,753.31
    -45.66 (-0.12%)
     

  • Nasdaq

    15,683.37
    -181.88 (-1.15%)
     

  • Gold

    2,382.30
    -6.10 (-0.26%)
     

  • Crude Oil

    82.79
    +0.10 (+0.12%)
     

  • 10-Yr Bond

    4.5850
    -0.0740 (-1.59%)
     

  • FTSE Bursa Malaysia

    1,541.81
    +1.39 (+0.09%)
     

  • Jakarta Composite Index

    7,162.99
    +32.15 (+0.45%)
     

  • PSE Index

    6,533.65
    +83.61 (+1.30%)
     

Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?

Alex Carchidi, The Motley Fool
·4-min read
Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?

Vaxart (NASDAQ: VXRT) is betting that, yes, people will prefer to avoid the pain of a jab if they have the option of taking its oral-pill vaccines. Now that there are a plethora of other coronavirus vaccines that are already approved for sale and actively gaining market share, can Vaxart still deliver for its investors? According to a (questionably rigorous) survey that Vaxart commissioned recently, 32% of the people in the U.S. who are not currently intending to get vaccinated for COVID-19 would be likely to do so if they could take a pill instead of getting an injection.

Continue reading